But understanding why this happens with semaglutide, tirzepatide and other GLP-1 drugs could be crucial to understanding their longer-term health consequences and how best to prescribe them in future
In the SUSTAIN6 trial, semaglutide (a GLP-1RA) significantly increased diabetic retinopathy complications, including vitreous hemorrhage [2], while a recent retrospective cohort study of patients with type 2 diabetes showed that use of GLP-1RAs modestly increased the incident risk of diabetic retinopathy, although sight-threatening diabetic complications including blindness were somewhat lower in patients treated with GLP-1 RAs [5]
its a science-backed approach to weight management
And for anyone who has experienced muscle cramping, fatigue, or headaches during or after exercise, low electrolytes are often a contributing factor worth addressing before assuming the cause is something else
The first two funds, VTI and VOO , provide overlapping exposure to domestic stocks
A Phase III trial of Exenatide in PD (NCT4232969) found that Exenatide was without clinical benefit [56]
